Royalty Pharma
RPRX
RPRX
529 hedge funds and large institutions have $13.8B invested in Royalty Pharma in 2025 Q4 according to their latest regulatory filings, with 102 funds opening new positions, 234 increasing their positions, 134 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
19% more capital invested
Capital invested by funds: $11.6B → $13.8B (+$2.22B)
9% more funds holding
Funds holding: 485 → 529 (+44)
7.68% more ownership
Funds ownership: 75.84% → 83.52% (+7.7%)
Holders
529
Holding in Top 10
14
Calls
$10.3M
Puts
$6.61M
Top Buyers
| 1 | +$424M | |
| 2 | +$186M | |
| 3 | +$148M | |
| 4 |
Jane Street
New York
|
+$68.5M |
| 5 |
RP
Regal Partners
Sydney, NSW,
Australia
|
+$46M |
Top Sellers
| 1 | -$80.8M | |
| 2 | -$65.4M | |
| 3 | -$52.9M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$41.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$38.2M |
